Authors

Latest:

Dr. Thierry Jahan on the CRS-207 Vaccine in Mesothelioma

Thierry M. Jahan, MD, a clinical professor in the Department of Medicine at the University of California San Francisco Helen Diller Family Comprehensive Cancer Center, discusses a phase Ib trial of CRS-207 in malignant pleural mesothelioma (MPM).

Thomas A. Abrams, MD, Harvard Medical School

Latest:

Dr. Abrams on Next Steps for Cabozantinib/Atezolizumab Combo in MSS/MMRp CRC

Thomas A. Abrams, MD, discusses the next steps for exploration of cabozantinib plus atezolizumab in the treatment of microsatellite stable and mismatch repair proficient colorectal cancer.

Thomas A. Hensing, MD

Latest:

Dr. Hensing Discusses Studies in Stage III NSCLC

Thomas A. Hensing, MD, co-director of the Thoracic Oncology Program at NorthShore University HealthSystem, discusses prospective studies in stage III non-small cell lung cancer (NSCLC).

Thomas A. Hope, MD

Latest:

Dr. Hope on Challenges With 68Ga-PSMA-11 PET in Prostate Cancer

Thomas Hope, MD, discusses challenges with 68Ga-PSMA-11 PET in men with intermediate- or high-risk prostate cancer.

Thomas A. Neville, PhD

Latest:

Thomas A. Neville, PhD, Discusses PSA Growth Rate

Thomas A. Neville, PhD, CEO of Soar Biodynamics in Incline Village, Nevada, discusses PSA growth rate.

Thomas Butler, MD

Latest:

Dr. Butler on the Importance of Health Literacy Initiatives

Thomas Butler, MD, associate professor of interdisciplinary clinical oncology, Mitchell Cancer Center, discusses the importance of health literacy initiatives at the Association of Community Cancer Center (ACCC) National Oncology Conference.

Thomas C. Krivak, MD

Latest:

Emerging ADCs in Advanced Endometrial Cancer: Anti-TROP2 and Anti-FR Agents

Panelists discuss recent data on emerging antibody-drug conjugates in advanced and recurrent endometrial cancer, including anti-TROP2 agents like sacituzumab govitecan from the TROPiCS-03 trial, datopotamab deruxtecan from TROPION-PanTumor03, and sacituzumab tirumotecan, as well as anti–folate receptor agents like luveltamab tazevibulin and rinatabart sesutecan, while offering future perspectives and closing thoughts on the evolving role of these agents in the treatment landscape for endometrial cancer.

Thomas D. Coates, MD

Thomas D. Coates, MD, University of Southern California Keck School of Medicine

Thomas E. Hutson, DO, Pharm.D., FACP

Latest:

An Individualized Approach to Treating Advanced RCC

Grounded in a collaborative and personalized approach, researcher and clinician Dr. Thomas Hutson expands on his best practices for treating certain people living with advanced RCC with a combination therapy.

Thomas E. Hutson, DO, PharmD, Baylor University Medical Center

Thomas E. Hutson, DO, PharmD, Texas Oncology

Latest:

Series Wrap-up: Novel Therapies for mRCC

A panel of expert oncologists who manage patients with renal cell carcinoma share enthusiasm over the use of newer novel-based treatment approaches for metastatic disease.

Thomas E. Stinchcombe, MD

Latest:

Dr. Stinchcombe on the ALTA-1L Trial in ALK+ NSCLC

Thomas E. Stinchcombe, MD, discusses the results of the randomized phase III ALTA-1L trial in ALK-positive non–small cell lung cancer.

Thomas E. Stinchcombe, MD, Duke Cancer Center

Thomas E. Stinchcombe, MD, Duke Cancer Institute

Thomas E. Stinchcombe, MD, Duke University Health System

Thomas E. Stinchcombe, MD, UNC

Thomas E. Stinchcombe, MD, University of North Carolina at Chapel Hill

Thomas E. Witzig, MD

Latest:

Dr. Witzig on Emerging Agents in Diffuse Large B-Cell Lymphoma

Thomas E. Witzig, MD, hematologist-oncologist, Mayo Clinic, discusses some of the emerging agents being utilized in the treatment of patients with diffuse large B-cell lymphoma.

Thomas F. Gajewski, MD, PhD

Latest:

Dr Gajewski on the Role of the Gut Microbiome in Immunotherapy Response Regulation

Thomas F. Gajewski, MD, PhD, discusses the mechanism through which the gut microbiome modulates myeloid cells to regulate responses to immunotherapy.